{"id":"lorcainide","rwe":[{"pmid":"33971179","year":"2021","title":"Inhibition of voltage-dependent K(+) channels in rabbit coronary arterial smooth muscle cells by the class Ic antiarrhythmic agent lorcainide.","finding":"","journal":"European journal of pharmacology","studyType":"Clinical Study"},{"pmid":"25630497","year":"2015","title":"The true lorcainide story.","finding":"","journal":"BMJ (Clinical research ed.)","studyType":"Clinical Study"},{"pmid":"24204014","year":"2014","title":"Identification of the antiarrhythmic drugs amiodarone and lorcainide as potent H3 histamine receptor inverse agonists.","finding":"","journal":"The Journal of pharmacology and experimental therapeutics","studyType":"Clinical Study"},{"pmid":"11730558","year":"2001","title":"Frequency dependent prolongation of effective refractory period by a complex class III antiarrhythmic agent CPU-86017.","finding":"","journal":"Acta pharmacologica Sinica","studyType":"Clinical Study"},{"pmid":"10593659","year":"1999","title":"Class I antiarrhythmic drug effects on ouabain binding to guinea pig cardiac Na+ -K+ ATPase.","finding":"","journal":"Canadian journal of physiology and pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"lorcainide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sodium channel protein type 5 subunit alpha","category":"target"},{"label":"SCN5A","category":"gene"},{"label":"SCN1B","category":"gene"},{"label":"SCN2B","category":"gene"},{"label":"C01BC07","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Arrhythmia Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"lorcamide","offLabel":[],"synonyms":["lorcainide hydrochloride","lorcainide","lorcamide","lorcainide HCl"],"timeline":[],"approvals":[],"brandName":"Lorcamide","ecosystem":[],"mechanism":{"target":"Sodium channel subunit beta-1, Sodium channel subunit beta-2, Sodium channel subunit beta-3","targets":[{"gene":"SCN5A","source":"DrugCentral","target":"Sodium channel protein type 5 subunit alpha","protein":"Sodium channel protein type 5 subunit alpha"},{"gene":"SCN1B","source":"DrugCentral","target":"Sodium channel subunit beta-1","protein":"Sodium channel subunit beta-1"},{"gene":"SCN2B","source":"DrugCentral","target":"Sodium channel subunit beta-2","protein":"Sodium channel subunit beta-2"},{"gene":"SCN3B","source":"DrugCentral","target":"Sodium channel subunit beta-3","protein":"Sodium channel subunit beta-3"},{"gene":"SCN4B","source":"DrugCentral","target":"Sodium channel subunit beta-4","protein":"Sodium channel subunit beta-4"}],"modality":"Small Molecule","drugClass":"lorcainide","explanation":"Imagine your heart is like a firework, with electrical signals that make it beat. Sometimes, these signals can get out of control and cause abnormal heart rhythms. Lorcainide helps to calm down these electrical signals by blocking the sodium channels that carry them, which helps to regulate the heartbeat.","oneSentence":"Lorcainide works by blocking sodium channels in the heart to regulate abnormal heart rhythms.","technicalDetail":"Lorcainide acts as a class Ic antiarrhythmic agent by selectively blocking the sodium channel protein type 5 subunit alpha, which reduces the inward sodium current and slows the conduction velocity in the heart, thereby stabilizing the cardiac rhythm."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1607","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LORCAINIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:24:55.665341","biosimilars":[],"competitors":[{"drugName":"propafenone","drugSlug":"propafenone","fdaApproval":"1989-11-27","genericCount":15,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"flecainide","drugSlug":"flecainide","fdaApproval":"1985-10-31","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"lorcainide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"propafenone","brandName":"propafenone","genericName":"propafenone","approvalYear":"1989","relationship":"same-class"},{"drugId":"flecainide","brandName":"flecainide","genericName":"flecainide","approvalYear":"1985","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"008142","UNII":"KGJ2T0N7IQ","CHEBI":"CHEBI:135568","INN_ID":"4143","UMLSCUI":"C0065183","ChEMBL_ID":"CHEMBL87543","KEGG_DRUG":"D04778","DRUGBANK_ID":"DB13653","PUBCHEM_CID":"42884","SECONDARY_CAS_RN":"58934-46-6","MESH_SUPPLEMENTAL_RECORD_UI":"C015970"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"6.5 hours","clearance":"16.0 mL/min/kg","fractionUnbound":"0.15%","volumeOfDistribution":"6.6 L/kg"},"publicationCount":146,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C01BC07","allCodes":["C01BC07"]},"biosimilarFilings":[],"recentPublications":[{"date":"2021 Aug 5","pmid":"33971179","title":"Inhibition of voltage-dependent K(+) channels in rabbit coronary arterial smooth muscle cells by the class Ic antiarrhythmic agent lorcainide.","journal":"European journal of pharmacology"},{"date":"2015 Jan 28","pmid":"25630497","title":"The true lorcainide story.","journal":"BMJ (Clinical research ed.)"},{"date":"2014 Jan","pmid":"24204014","title":"Identification of the antiarrhythmic drugs amiodarone and lorcainide as potent H3 histamine receptor inverse agonists.","journal":"The Journal of pharmacology and experimental therapeutics"},{"date":"2001 Jan","pmid":"11730558","title":"Frequency dependent prolongation of effective refractory period by a complex class III antiarrhythmic agent CPU-86017.","journal":"Acta pharmacologica Sinica"},{"date":"1999 Nov","pmid":"10593659","title":"Class I antiarrhythmic drug effects on ouabain binding to guinea pig cardiac Na+ -K+ ATPase.","journal":"Canadian journal of physiology and pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lorcainide is a small molecule drug in the class of lorcainide, targeting the sodium channel protein type 5 subunit alpha. It is used to treat certain heart rhythm disorders. However, its commercial status and approved indications are unknown. Lorcainide has a half-life of 6.5 hours, but its bioavailability and off-patent status are not specified. As a result, its availability and usage may be limited.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}